Table 2.
Laboratory parameters of total study population (N=286) over time before and after switching from tenofovir DF to abacavir
| Parameter (reference range) [20] | Baseline on TDF | At 3 months on ABC | At 6 months on ABC | At 12 months on ABC |
|---|---|---|---|---|
| CD4, cells/mm3 (410–1130) | 500 (350–660) | 500 (350–700)** | 550 (398–710)* | 550 (410–740)* |
| pVL<50 copies/mL | 95.8% | 94.2% | 93.2% | 94.4% |
| Creatinine, µmol/L (45–110) | 93 (80–111) | 90 (79–99)* | 89 (77–99)* | 88 (78–98)* |
| eGFR, mL/min (>59) | 74 (60–88) | 78 (67–90)* | 81 (69–91)* | 80 (69–89)* |
| Phosphorus, mmol/L (0.8–1.5) | 0.91 (0.74–1.04) | 0.94 (0.81–1.06) | 0.94 (0.82–1.06) | 0.92 (0.77–1.03) |
| UACR, mg/mmol (<2.0) | 2.80 (0.80–10.30) | 1.40 (0.90–8.10)* | 1.30 (0.70–4.60)* | 1.60 (0.80–4.70)* |
| Total cholesterol, mmol/L (<5.20) | 4.35 (3.86–5.17) | 5.23 (4.51–5.84)* | 5.11 (4.35–5.64)* | 4.94 (4.31–5.63)* |
| LDL, mmol/L (<3.4) | 2.52 (2.11–3.17) | 2.63 (2.25–3.63) | 2.69 (2.26–3.42)** | 2.64 (2.14–3.18) |
| HDL, mmol/L (>0.90) | 1.17 (0.97–1.36) | 1.22 (1.06–1.51)* | 1.21 (1.02–1.56)* | 1.22 (1.10–1.52)* |
| Triglycerides, mmol/L (<1.50) | 1.40 (1.00–2.13) | 1.86 (1.52–2.97)* | 1.62 (1.19–2.65)* | 1.86 (1.35–2.73)* |
Data shown as median (interquartile range) except plasma viral load (pVL), shown as percentage of the total study population. TDF, tenofovir disoproxil fumarate; ABC, abacavir; eGFR, estimated glomerular filtration rate (MDRD formula); UACR, urine albumin to creatinine ratio.
*
p<0.001 for change from baseline.
**
p<0.05 for change from baseline.